Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 18 | 2025 | 2495 | 1.870 |
Why?
|
| Alopecia | 3 | 2018 | 38 | 1.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 1207 | 1.140 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 50 | 0.580 |
Why?
|
| Receptor, ErbB-2 | 6 | 2024 | 514 | 0.540 |
Why?
|
| Scalp | 1 | 2017 | 57 | 0.530 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 165 | 0.490 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2022 | 235 | 0.490 |
Why?
|
| Quinolines | 4 | 2024 | 98 | 0.450 |
Why?
|
| Quality of Life | 3 | 2018 | 1899 | 0.390 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 83 | 0.390 |
Why?
|
| RANK Ligand | 1 | 2012 | 52 | 0.380 |
Why?
|
| Plasmacytoma | 1 | 2011 | 7 | 0.380 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1652 | 0.370 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 63 | 0.340 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 170 | 0.320 |
Why?
|
| Brain Neoplasms | 3 | 2024 | 1210 | 0.290 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 416 | 0.280 |
Why?
|
| Neoplasms | 2 | 2018 | 2762 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 1018 | 0.260 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 282 | 0.240 |
Why?
|
| Patient Preference | 1 | 2025 | 116 | 0.220 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 73 | 0.210 |
Why?
|
| Female | 23 | 2025 | 66250 | 0.210 |
Why?
|
| Social Support | 1 | 2025 | 329 | 0.210 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2022 | 38 | 0.200 |
Why?
|
| Proteogenomics | 1 | 2022 | 67 | 0.190 |
Why?
|
| Estrogen Antagonists | 1 | 2022 | 103 | 0.190 |
Why?
|
| Biomarkers, Tumor | 5 | 2023 | 1474 | 0.190 |
Why?
|
| Humans | 27 | 2025 | 124122 | 0.170 |
Why?
|
| Adenomyoepithelioma | 1 | 2019 | 1 | 0.170 |
Why?
|
| Aged | 10 | 2025 | 19526 | 0.170 |
Why?
|
| Caregivers | 1 | 2025 | 557 | 0.160 |
Why?
|
| Cholecalciferol | 1 | 2019 | 22 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 329 | 0.160 |
Why?
|
| Arthralgia | 1 | 2019 | 54 | 0.160 |
Why?
|
| Aromatase Inhibitors | 1 | 2019 | 76 | 0.160 |
Why?
|
| Middle Aged | 13 | 2025 | 26583 | 0.150 |
Why?
|
| Hair Diseases | 1 | 2018 | 14 | 0.150 |
Why?
|
| Cryotherapy | 1 | 2018 | 25 | 0.150 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2018 | 5 | 0.150 |
Why?
|
| STAT5 Transcription Factor | 1 | 2018 | 89 | 0.140 |
Why?
|
| Paclitaxel | 2 | 2015 | 124 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 256 | 0.140 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 66 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2018 | 133 | 0.140 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 16 | 0.140 |
Why?
|
| Bridged-Ring Compounds | 1 | 2017 | 17 | 0.140 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 131 | 0.140 |
Why?
|
| Anthracyclines | 1 | 2017 | 36 | 0.140 |
Why?
|
| Taxoids | 1 | 2017 | 67 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2019 | 413 | 0.130 |
Why?
|
| Primary Prevention | 1 | 2017 | 168 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2015 | 504 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 70 | 0.110 |
Why?
|
| Adult | 9 | 2025 | 29322 | 0.110 |
Why?
|
| Neoplasm Metastasis | 3 | 2025 | 663 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2011 | 355 | 0.100 |
Why?
|
| Jejunal Neoplasms | 1 | 2012 | 5 | 0.100 |
Why?
|
| Nanoparticles | 1 | 2015 | 235 | 0.100 |
Why?
|
| Risk Factors | 3 | 2021 | 10241 | 0.100 |
Why?
|
| Phyllodes Tumor | 1 | 2012 | 11 | 0.100 |
Why?
|
| Jejunal Diseases | 1 | 2012 | 15 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2021 | 3427 | 0.100 |
Why?
|
| Denosumab | 1 | 2012 | 13 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 726 | 0.100 |
Why?
|
| Intussusception | 1 | 2012 | 46 | 0.090 |
Why?
|
| Trastuzumab | 2 | 2023 | 134 | 0.090 |
Why?
|
| Mastectomy, Segmental | 2 | 2022 | 27 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 116 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2022 | 140 | 0.090 |
Why?
|
| Bone Marrow | 1 | 2011 | 324 | 0.080 |
Why?
|
| Apoptosis | 3 | 2018 | 1778 | 0.080 |
Why?
|
| Skin | 1 | 2011 | 517 | 0.070 |
Why?
|
| Breast | 2 | 2019 | 216 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2023 | 12275 | 0.070 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 145 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 1233 | 0.060 |
Why?
|
| Prognosis | 3 | 2022 | 4608 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2005 | 85 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 90 | 0.060 |
Why?
|
| Safety-net Providers | 1 | 2025 | 52 | 0.060 |
Why?
|
| Survival Rate | 2 | 2019 | 2035 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2087 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 21 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 76 | 0.050 |
Why?
|
| Quinazolines | 1 | 2023 | 174 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 409 | 0.050 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2022 | 29 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2022 | 60 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 676 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2025 | 535 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 544 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 6465 | 0.050 |
Why?
|
| Palliative Care | 1 | 2025 | 427 | 0.040 |
Why?
|
| Oxazepines | 1 | 2019 | 1 | 0.040 |
Why?
|
| Glioma | 1 | 2005 | 489 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 12 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2025 | 540 | 0.040 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2019 | 35 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 606 | 0.040 |
Why?
|
| Benzamides | 1 | 2019 | 106 | 0.040 |
Why?
|
| Capecitabine | 1 | 2019 | 16 | 0.040 |
Why?
|
| Nitriles | 1 | 2019 | 146 | 0.040 |
Why?
|
| Proteomics | 1 | 2022 | 496 | 0.040 |
Why?
|
| Craniotomy | 1 | 2019 | 108 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 382 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 163 | 0.040 |
Why?
|
| Pimozide | 1 | 2018 | 6 | 0.040 |
Why?
|
| Imidazoles | 1 | 2019 | 194 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 356 | 0.040 |
Why?
|
| Hyperprolactinemia | 1 | 2018 | 23 | 0.040 |
Why?
|
| Pigmentation Disorders | 1 | 2018 | 23 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 723 | 0.040 |
Why?
|
| Risperidone | 1 | 2018 | 59 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 681 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2047 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 611 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 796 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 353 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 530 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 34002 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 476 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2015 | 11 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1369 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 89 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3682 | 0.030 |
Why?
|
| Albumins | 1 | 2015 | 87 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 397 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 252 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 361 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1629 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 3046 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 664 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 1238 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1699 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 411 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1889 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2018 | 4498 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2882 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 4778 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5132 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 2979 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 8983 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 23 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2005 | 37 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2005 | 152 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 619 | 0.010 |
Why?
|
| Male | 2 | 2025 | 60978 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 481 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 17582 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 3328 | 0.010 |
Why?
|